FULC FY 2024 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$80M+2752.0% YoY

Gross Profit

$17M20.8% margin

Operating Income

-$22M-27.4% margin

Net Income

-$10M-12.2% margin

EPS (Diluted)

$-0.16

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$261M

Total Liabilities

$18M

Stockholders' Equity

$243M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$80M	$3M	+2752.0%
Gross Profit	$17M	$3M	+492.3%
Operating Income	-$22M	-$111M	+80.2%
Net Income	-$10M	-$97M	+90.0%